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In January 2019, five of 11 travellers to Koh Lanta, 
Thailand, contracted chikungunya, symptoms start-
ing 4 days after presumed transmission. Four cases 
were hospitalised, one child treated in intensive care; 
6 weeks after disease onset, all three adults have 
persistent arthralgias/arthritis, incapacitating for 
two. Together with a recent report of eight chikungu-
nya cases among travellers to various destinations in 
Thailand, the high attack rate in our cluster points to 
an ongoing outbreak in the country.
Recently, eight chikungunya cases were reported from 
various European countries and Israel, all returning 
from Thailand between November 2018 and February 
2019 [1]. Here, we report a cluster of five chikungunya 
cases among 11 family members visiting Koh Lanta, 
an island district in Krabi Province, in the south of 
Thailand, in January 2019. Three of the eight cases in 
the earlier report had visited the same destination as 
this family [1].
Case description
A vacation was taken by a group comprising 11 relatives 
in four family units: family one (adult family members 
1–2), family two (adult family members 3–4 and chil-
dren family members 5–6), family three (family mem-
bers 7–8); family four (family members 9–11), resided 
at the same hotel in a popular tourist destination Koh 
Lanta, Thailand from mid-January 2019, having meals 
together. The ages of the family members ranged from 
9 to 70 years, nine were adults, five were male. Their 
holiday trips were planned to last 1 or 2 weeks; family 
4 returned to Finland after 1 week as scheduled.
On day 9 of their stay, family 2 (members 3–6) spent 
the evening on the beach practicing sports, while fami-
lies 1 and 3 only visited the beach briefly. The follow-
ing day, members of the local population mentioned 
that there had been an unusually high number of 
mosquitoes, a ‘mosquito invasion’, the evening before. 
Family members 3–6 had applied mosquito repellents 
that morning and reported only a few bites, while fam-
ily member 1 had not used any repellent and reported 
60–70 mosquito bites all over his legs. Family mem-
bers 3–6 and family member 1 all fell ill 4–6 days later 
(days 23–25 of stay in Thailand) with a systemic febrile 
disease and arthralgias. A description of the cases (in 
the order of symptom onset) can be seen in Table 1.
Family 2 was scheduled to return home after a stay 
of 14 days, but due to the severity of disease in the 
children (family members 5 and 6), the flight was 
postponed by 1 week. On return to Finland, the chil-
dren were further hospitalised. On 1 March (38 days 
after presumed transmission), the children are back 
at school with minor arthralgias remaining. Family 
member 1 continues to have severe polyarthralgia and 
arthritis, but cannot use nonsteroidal anti-inflamma-
tory drugs (NSAIDs) due to other medications, and has 
therefore been referred to a rheumatologist. Family 
member 3 has asthma as underlying disease; while 
her condition improved with a low dose etoricoxib (30 
mg OD), higher doses resulted in an allergic reaction. 
Referral to a rheumatologist is planned if further clini-
cal improvement under ibuprofen therapy (600 mg TD) 
is not observed. Family member 4 has arthralgia, but 
he manages on ibuprofen medication.
Discussion
Febrile systemic diseases in Thailand are not as com-
mon as other travel-related health problems like diar-
rhoea [2,3], but often are more severe. Febrile systemic 
diseases include a large variety of mosquito-borne 
infections such as malaria, lymphatic filariasis and 
viral infections caused by Japanese encephalitis, zika, 
dengue and chikungunya viruses [4,5]. Prevention 
of these diseases relies heavily on mosquito avoid-
ance, as vaccines are currently only available for 
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Other laboratory tests in Finland 










Return had to be delayed by 
one week; 
 
hospitalised in Thailand 
and in Finland; persistent 




Evaluation on 1 March (day 
35): 
 
Recovered fairly quickly 
after return to Finland, only 
minor arthralgias left
















by ELISA (day 
11)
Hb 103; leuc 8.2; tromb 541; eos 
0.17; CRP 51; LD 266; 
 
blood culture negative; PCR 
for bacterial stool pathogens: 
enteroaggregative E. coli; stool 
PCR for protozoa negative; 
malaria tick and thin blood 
smears negative; influenza A and 
B by RDT negative; NS1 antigen 















Return had to be delayed 
by one week; intensive care 
in Thailand, treatment with 
intravenous ceftriaxone; 
hospitalised in Finland; 





Evaluation on 1 March (day 
35): 
 
Clinical picture initially more 
severe than for the others. 
Recovered fairly quickly 
after return to Finland, only 
minor arthralgias left.
RDT for dengue 
weak positive 
 


















Hb 133; leuc 4.2; tromb 463; eos 
0.08; CRP < 3; ALAT 43; LD 326; 
 
blood culture negative; PCR 
for bacterial stool pathogens: 
negative; stool PCR for 
protozoa: negative; NS1 
antigen and dengue virus 
antibodies negative; MDR 
colonisation negative for 
















itching of skin 
(no rash)
Hospitalised in Thailand; 
persistent arthralgia in 
fingers, wrists and neck, 
clinical arthritis and 
tenosynovitis in right 
foot. Substantial walking 
difficulties, impaired 





Evaluation on 1 March (day 
35): 
 
Due to rivaroxaban 
medication, non-steroidal 
anti-inflammatory agents 
contraindicated. Received a 
one-week course of steroids 
 
Disabling arthralgias and 
arthritis continue; 
 
Visited today a 
rheumatologist and was 
given intra-articular steroids 












Hb 148; leuc 8.2; tromb 272; 
eos 0.08; CRP < 3; ALAT 73; stool 
culture for Salmonella, Shigella, 
Campylobacter, Yersinia: 
negative; NS1 antigen and 
dengue virus antibodies negative 
 
(day 25)
ALAT: alanine aminotransferase; CRP: C-reactive protein; CHIKV: chikungunya virus; SPE: carbapenemase-producing Enterobacteriaceae; CRP: 
C-reactive protein; EIA: enzyme-immuno assay; eos: eosinophils; ESBL-PE: extended-spetrum beta-lactamase-producing Enterobacteriaceae; 
Hb: haemoglobin; LD: lactate dehydrogenase; Leuc: leucocyte; MRSA: methicillin resistant Staphylococcus aureus; NS1: non-structural protein 
1; PCR: polymerase chain reaction; RDT: rapid diagnostic test; tromb: trombocytes; VRE: vancomycin-resistant Enterococcus faecalis.
Normal values: CRP (< 3 mg/l); eos (0.03-0-44 E9/l); Hb (117-156 g/l); LD (115-235 U/l); leuc (3.4-8.2 E9/l); tromb (150-360 E9/l).
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Japanese encephalitis [5]. Chikungunya virus (CHIKV) 
is transmitted, like dengue and zika viruses, by Aedes 
aegypti and Aedes albopictus mosquitoes [4,5] and has 
an incubation period of 3–7 days, symptoms beginning 
with an abrupt onset of fever followed by a predominat-
ing symptom of severe, sometimes disabling, polyar-
thralgia [6]. Some patients also develop a rash [6].
High attack rates of chikungunya pose a risk for tourists 
in areas where there is local transmission. Travellers 
can act as sentinels of outbreaks in a region. The clus-
ter we present here accords with the findings by Javelle 
et al. [1] concerning Geosentinel sites describing a peak 
in chikungunya cases among visitors to Thailand. Of 
particular interest in our cluster is the high attack rate 
– with five of 11 travellers contracting chikungunya, all 
among the eight who stayed for longer than 1 week.
If, on return to their home countries, travellers are 
still viraemic and  Aedes  vectors prevail in their 
home country, there could be a risk of disease 
spread.  Ae. albopictus  appears to be the main 
vector for most of the European Union and European 
Economic Area, with Madeira as an exception since 
it also has an established  Ae. aegypti  population 
[7].  Aedes  mosquitoes are only found in certain parts 
of central and southern Europe and the transmission 
period depends on temperature, usually not beginning 
before late spring [8].
In our cluster, four of the five cases had to be hospi-
talised in Thailand and one of the children required 
treatment in an intensive care unit. Severe manifesta-
tions and even deaths are seen in outbreaks, mostly 
among the elderly or those with underlying diseases 
[6]. Indeed, in our cluster, the two children had the 
Table 1b

















Other laboratory tests in Finland 












Return home had to be 







Evaluation on 1 March (day 
34): 
 
Started on day 13 after 
symptom onset with 
etoricoxib low dose (30 
mg), gradually increasing 
to 90 mg, then rash; now 
receiving ibuprofen, walking 
difficulties, will be referred 
to a rheumatologist unless 
starts to improve soon.











Hb 148; leuc 4.6, part of 
lymphocytes reactive, a few 
plasma cells; tromb 286; eos 
0.05; CRP 51; ALAT 39; ASAT 18; 
blood culture negative; stool PCR 
for bacteria: enteropathogenic E. 
coli; NS1 antigen negative; 





(family member 4) None
Fever; 
arthralgia, 
strong pain in 
heels, causing 
inability to walk, 
pain also in left 
knee, wrists, 
ankles; itching 
of skin (no rash)
Hospitalised in Thailand 
until day 4 after onset of 
symptoms; 
 
Return had to be delayed 





Evaluation on 1 March (day 
33): 
 
Started on day 20 after 
symptom onset ibuprofen; 
arthralgias continue but 
are improving and patient 

























Hb 157; leuc 8.6; tromb 415; eos 
0.14; CRP < 3; ALAT 26; 
 
NS1 antigen and dengue virus 
antibodies by EIA negative 
 
(day 26)
ALAT: alanine aminotransferase; CRP: C-reactive protein; CHIKV: chikungunya virus; SPE: carbapenemase-producing Enterobacteriaceae; CRP: 
C-reactive protein; EIA: enzyme-immuno assay; eos: eosinophils; ESBL-PE: extended-spetrum beta-lactamase-producing Enterobacteriaceae; 
Hb: haemoglobin; LD: lactate dehydrogenase; Leuc: leucocyte; MRSA: methicillin resistant Staphylococcus aureus; NS1: non-structural protein 
1; PCR: polymerase chain reaction; RDT: rapid diagnostic test; tromb: trombocytes; VRE: vancomycin-resistant Enterococcus faecalis.
Normal values: CRP (< 3 mg/l); eos (0.03-0-44 E9/l); Hb (117-156 g/l); LD (115-235 U/l); leuc (3.4-8.2 E9/l); tromb (150-360 E9/l).
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most severe clinical picture in the acute phase and 
recovered fairly rapidly, whereas the symptoms per-
sist longer among the adults: now, 6 weeks after the 
presumed transmission, the two children are nearly 
asymptomatic, while the three adults still have arthal-
gias/arthritis, for two of them incapacitating.
In one adult case, an underlying disease prevents 
the use of NSAIDs for post-acute chikungunya. 
Antirheumatic medications such as methotrexate and 
hydroxychloroquine are recommended alternatives, if 
the NSAIDs cannot be used [9]; while corticosteroids 
should not be taken in the acute phase, they may be 
needed in the chronic stage. Despite treatment, how-
ever, severe joint problems may continue for months or 
even years [6].
While travellers may act as sentinels of outbreaks in a 
destination, the peak observed in chikungunya cases in 
Thailand [1] calls for enhanced prevention also among 
forthcoming travellers. There is no vaccine available 
against chikungunya, and mosquito avoidance remains 
the sole preventive approach. Indeed, it also protects 
against dengue and zika viruses transmitted by the 
same mosquito species; even co-infections have been 
described [10,11]. Many travellers use mosquito repel-
lents especially at dusk and dawn, the time malaria-
transmitting  Anopheles  mosquitoes bite. However, 
since the Aedes mosquitoes mostly bite in the daytime 
[4,8], to shield themselves against chikungunya, den-
gue and zika viruses, travellers should also be advised 
to apply repellents during the day.
Thailand is a popular tourist destination in the world: 
in 2017 there were over 35 million visitors, 6.5 million 
arriving from Europe [12]. Many travellers to Thailand 
do not seek pre-travel advice [13] and it is thus a chal-
lenge reach them. Travel agencies, insurance compa-
nies and other actors outside the medical community 
should be approached as additional channels to reach 
out to tourists and deliver relevant information.
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